In 2023, T-DXd was also approved for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received at least two prior lines of endocrine therapy in addition to one line of chemotherapy in the metastatic setting or following disease recurrence during or within 6 months of completion of adjuvant chemotherapy. Here, ERBB2 is linked to breast carcinoma.